Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pilar Lim

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Progress in Neuro-Psychopharmacology & Biological Psychiatry|June 2, 2009
Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophreniaDavid Hough, Jean-Pierre Lindenmayer, Srihari Gopal, et al.
The International Journal of Neuropsychopharmacology|July 23, 2011
A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophreniaW Wolfgang Fleischhacker, Srihari Gopal, Rosanne Lane, et al.
CNS Spectrums|August 13, 2010
One-year open-label safety and efficacy study of paliperidone extended-release tablets in patients with schizophreniaMichelle Kramer, George Simpson, Valentinas Maciulis, et al.
Bipolar Disorders|June 23, 2010
A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorderEduard Vieta, Isaac F Nuamah, Pilar Lim, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 18, 2010
A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophreniaHenry A Nasrallah, Srihari Gopal, Cristiana Gassmann-Mayer, et al.
Journal of Clinical Psychopharmacology|May 18, 2010
A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophreniaGahan J Pandina, Jean-Pierre Lindenmayer, Julia Lull, et al.
The Journal of Clinical Psychiatry|May 16, 2020
Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I)Dong-Jing Fu, Dawn F Ionescu, Xiang Li, et al.
The International Journal of Neuropsychopharmacology|August 30, 2020
Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)Dawn F Ionescu, Dong-Jing Fu, Xin Qiu, et al.
The American Journal of Psychiatry|April 17, 2018
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled StudyCarla M Canuso, Jaskaran B Singh, Maggie Fedgchin, et al.
Focus (American Psychiatric Publishing)|February 5, 2020
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled StudyCarla M Canuso, Jaskaran B Singh, Maggie Fedgchin, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Progress in Neuro-Psychopharmacology & Biological Psychiatry|June 2, 2009
Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophreniaDavid Hough, Jean-Pierre Lindenmayer, Srihari Gopal, et al.
The International Journal of Neuropsychopharmacology|July 23, 2011
A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophreniaW Wolfgang Fleischhacker, Srihari Gopal, Rosanne Lane, et al.
CNS Spectrums|August 13, 2010
One-year open-label safety and efficacy study of paliperidone extended-release tablets in patients with schizophreniaMichelle Kramer, George Simpson, Valentinas Maciulis, et al.
Bipolar Disorders|June 23, 2010
A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorderEduard Vieta, Isaac F Nuamah, Pilar Lim, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 18, 2010
A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophreniaHenry A Nasrallah, Srihari Gopal, Cristiana Gassmann-Mayer, et al.
Journal of Clinical Psychopharmacology|May 18, 2010
A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophreniaGahan J Pandina, Jean-Pierre Lindenmayer, Julia Lull, et al.
The Journal of Clinical Psychiatry|May 16, 2020
Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I)Dong-Jing Fu, Dawn F Ionescu, Xiang Li, et al.
The International Journal of Neuropsychopharmacology|August 30, 2020
Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)Dawn F Ionescu, Dong-Jing Fu, Xin Qiu, et al.
The American Journal of Psychiatry|April 17, 2018
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled StudyCarla M Canuso, Jaskaran B Singh, Maggie Fedgchin, et al.
Focus (American Psychiatric Publishing)|February 5, 2020
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled StudyCarla M Canuso, Jaskaran B Singh, Maggie Fedgchin, et al.
Pageof 5